Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Tompkins Financial Corp

Tompkins Financial Corp cut its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 59.1% during the 1st quarter, HoldingsChannel.com reports. The fund owned 104 shares of the medical instruments supplier’s stock after selling 150 shares during the period. Tompkins Financial Corp’s holdings in Becton, Dickinson and Company were worth $26,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Ontario Teachers Pension Plan Board increased its holdings in Becton, Dickinson and Company by 3.8% during the 4th quarter. Ontario Teachers Pension Plan Board now owns 1,852,278 shares of the medical instruments supplier’s stock worth $451,641,000 after purchasing an additional 68,509 shares during the last quarter. Sapient Capital LLC purchased a new stake in Becton, Dickinson and Company during the 4th quarter worth approximately $1,295,000. Vest Financial LLC increased its holdings in Becton, Dickinson and Company by 27.5% during the 4th quarter. Vest Financial LLC now owns 103,004 shares of the medical instruments supplier’s stock worth $25,115,000 after purchasing an additional 22,207 shares during the last quarter. Caden Capital Partners LP increased its holdings in Becton, Dickinson and Company by 26.7% during the 4th quarter. Caden Capital Partners LP now owns 83,417 shares of the medical instruments supplier’s stock worth $20,340,000 after purchasing an additional 17,599 shares during the last quarter. Finally, SG Americas Securities LLC increased its holdings in Becton, Dickinson and Company by 69.4% during the 4th quarter. SG Americas Securities LLC now owns 15,113 shares of the medical instruments supplier’s stock worth $3,685,000 after purchasing an additional 6,190 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Roland Goette sold 3,300 shares of the company’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $236.70, for a total transaction of $781,110.00. Following the completion of the transaction, the executive vice president now directly owns 14,608 shares in the company, valued at approximately $3,457,713.60. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, SVP Thomas J. Spoerel sold 300 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $239.31, for a total value of $71,793.00. Following the completion of the transaction, the senior vice president now owns 1,976 shares of the company’s stock, valued at $472,876.56. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Roland Goette sold 3,300 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $236.70, for a total value of $781,110.00. Following the completion of the transaction, the executive vice president now directly owns 14,608 shares of the company’s stock, valued at approximately $3,457,713.60. The disclosure for this sale can be found here. Insiders sold a total of 8,615 shares of company stock worth $2,033,381 in the last three months. 0.31% of the stock is owned by insiders.

Analyst Ratings Changes

BDX has been the topic of several analyst reports. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Friday, June 14th. The Goldman Sachs Group initiated coverage on Becton, Dickinson and Company in a report on Thursday, May 30th. They set a “buy” rating and a $274.00 price objective on the stock. Finally, Barclays lifted their price objective on Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a report on Monday, May 6th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $280.17.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX traded up $0.98 during trading on Wednesday, reaching $233.73. The stock had a trading volume of 1,035,778 shares, compared to its average volume of 1,552,670. Becton, Dickinson and Company has a one year low of $224.00 and a one year high of $287.32. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41. The stock has a market cap of $67.55 billion, a PE ratio of 51.48, a P/E/G ratio of 2.04 and a beta of 0.44. The firm’s 50 day moving average price is $234.33 and its two-hundred day moving average price is $237.83.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The business had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. During the same period in the previous year, the business earned $2.86 EPS. The business’s quarterly revenue was up 4.6% on a year-over-year basis. On average, research analysts forecast that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be paid a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a yield of 1.63%. Becton, Dickinson and Company’s payout ratio is currently 83.70%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.